Picture ConsulTech GmbH Forschungszulage 650x80px
Document › Details

InflaRx GmbH. (7/17/14). "Press Release: InflaRx Announces Successful Closing of Its Round B Financing". Jena.

Region Region Jena
  Country Germany
Organisations Organisation InflaRx GmbH
  Group InflaRx (Group)
  Organisation 2 bm-t Beteiligungsmanagement Thüringen GmbH (bm|t)
  Group Thuringia (govt region)
Products Product IFX-1 (InflaRx)
  Product 2 venture capital
Index term Index term InflaRx–SEVERAL: investment, 201407 financing round Series B closing of 2nd + last tranche led by bm-t Thüringen
Persons Person Riedemann, Niels C. (InflaRx 200803 Managing Director + founder)
  Person 2 Werner, Udo (Thuringia (govt) 201309– Managing Director of bm-t GmbH before CyBio AG + TechnoTrend + McKinsey)

InflaRx announced today the successful closing of its round B financing by completing the second of two tranches within this round. All current investors as well as new private investors participated in this financing round B reaching an investment volume in the double digit million Euro space. The proceeds of this round will enable clinical phase II development of IFX-1, the first-in-class anti complement lead drug monoclonal antibody, in different acute inflammatory indications. In addition, the company explained that this funding shall foster pre-clinical development of IFX-2 as follow on antibody for the treatment of selected chronic inflammatory diseases and enable the development of a new bedside complement activation test in collaboration with a diagnostic partner.

Supported by the lead investment of the bm|t (beteiligungsmanagement thüringen gmbh) and other key stakeholders, InflaRx managed to build a global network of private business investors. "We are very happy being able to close this round with committed and excited investors especially in the current financial environment in Europe" says Prof. Niels Riedemann, co-founder and CEO of the company. "InflaRx offers a very exciting technology and has been able to establish a strong track record of delivering its set milestones", ads Udo Werner, CEO of bm|t.

The company has recently been awarded the IQ Innovation Award in Germany for its anti-complement technology. InflaRx has started its first phase IIa trial with IFX-1 in 2014 targeting infectious organ dysfunction in acutely site specific septic patients. In addition the company is setting up a second phase II trial preventing systemic inflammation and organ dysfunction in large scale surgery. Additional clinical programs are in the pipeline. "During the past 6.5 years, we have focused on delivering a first-in-class technology targeting a key player of inflammation and have now enlarged our technology base to target both, acute and chronic inflammatory diseases" explains Prof. Renfeng Guo, co-founder and CSO of InflaRx. - "We believe that our technology has the potential to change clinical practice in the field of inflammation and to provide benefit in areas of large medical need. This is what motivates and drives our entire team", ads Niels Riedemann.

About InflaRx GmbH

About bm|t beteiligungsmanagement thüringen gmbh

bm|t acts as the management company of six Thüringen dedicated investment funds, the TI - Thüringer Innovationsfonds, VCT (Venture Capital Thüringen GmbH & Co. KG), TIB (Thüringer Industriebeteiligungs GmbH & Co. KG), PET-I (Private Equity Thüringen GmbH & Co. KG) and PET-II (Private Equity Thüringen GmbH & Co. Zweite Beteiligungen KG) and ThGF (Thüringer Gründerfonds). As of today, bm|t manages a portfolio of 40 companies located in Thüringen (Germany) for a total of more than EURO 230M under management.


InflaRx GmbH
Prof. Dr. Niels C. Riedemann
Tel: +49-3641-508180


bm|t beteiligungsmanagement thüringen gmbh
Mr. Udo Werner
Tel: +49-361-7447-600

Record changed: 2017-04-02


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for InflaRx (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81

» top